FDA Determines Regulatory Review Period for EPKINLY Patent Extension

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for EPKINLY, a human biological product, and is publishing the notice as required by law, following submissions to the US Patent and Trademark Office (USPTO) for patent extension.